Quantifying drug release from PLGA nanoparticulates

Corrigan, Owen I.; Xue, Li

doi:10.1016/j.ejps.2009.04.004

Cited by 169 publications

(115 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In many studies to date, the influence of changing numerous process parameters -such as the amount of polymer and drug used, the time for preparation, and the selected excipients (different emulsifier or release modifier) -on particles produced via the double emulsion method has been described (Buske et al, 2012;Corrigan and Li, 2009;Cruz et al, 2011;Feczkó et al, 2011;Mundargi et al, 2008). However, for comparison of the potential of a polymer to act as an encapsulation material it is of utmost importance to keep the majority of process parameters unchanged.…”

Section: Results and Disussionmentioning

confidence: 99%

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

Rietscher

Czaplewska

Majdanski

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

Section: Results and Disussionmentioning

confidence: 99%

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

Rietscher

Czaplewska

Majdanski

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Size exclusion chromatography [58][59][60] Surface chemistry analysis X-ray photoelectron spectroscopy 28,61,62 Fourier transform infrared spectroscopy 54,63,64 Nuclear magnetic resonance spectroscopy [64][65][66] Surface charge Zetasizer 56,67,68 Crystallinity X-ray diffraction 37,69,70 Differential scanning calorimetry [71][72][73] Hydrophobicity, hydrophilicity water contact angle measurements 65,74,75 Hydrophobic interaction chromatography [76][77][78] Drug entrapment efficiency, drug release studies…”

Section: Molecular Weightmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

390

265

View full text Add to dashboard Cite

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.

show abstract

“…This can also be ascribed to the presence of the nanonized adsorbed drug on to the SLN surfaces and the subsequent enhanced dissolution rate. Then, the decreased rate of drug release was observed, which indicated the release of incorporated drug from the interiors of the nanoparticle (Corrigan & Li, 2009). It is assumed that the rate of release in second episode is maintained by diffusion of drug over the lipid matrix.…”

Section: In Vitro Drug Release Evaluationmentioning

confidence: 99%

Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations

et al. 2015

View full text Add to dashboard Cite

Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side effects. Its poor brain penetration results in lower bioavailability to the target site. With an aim to overcome these limitations, solid-lipid nanoparticulate formulation of galantamine hydrobromide was developed employing biodegradable and biocompatible components. The selected galantamine hydrobromide-loaded solid-lipid nanoparticles offered nanocolloidal with size lower than 100 nm and maximum drug entrapment 83.42 ± 0.63%. In vitro drug release from these spherical drug-loaded nanoparticles was observed to be greater than 90% for a period of 24 h in controlled manner. In vivo evaluations demonstrated significant memory restoration capability in cognitive deficit rats in comparison with naive drug. The developed carriers offered approximately twice bioavailability to that of plain drug. Hence, the galantamine hydrobromide-loaded solid-lipid nanoparticles can be a promising vehicle for safe and effective delivery especially in disease like Alzheimer's.

show abstract

Quantifying drug release from PLGA nanoparticulates

Cited by 169 publications

References 57 publications

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations

Contact Info

Product

Resources

About